[Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].

Abstract

Interleukin-1 (IL-1) is one of the main inflammatory mediators associated with development of rheumatoid arthritis (RA). Deficiency in secretion of the natural IL-1 antagonist was found in RA patients, and enhanced joint inflammation. This finding was confirmed by numerous studies using the animal model of the disease. Two randomized, multicenter clinical trials with anakinra, a recombinant IL-1 receptor antagonist (rHHHuIL-1Ra), revealed that application of anakinra with or without methotrexate induces remission (ACR 20) in 38-71% of patients with RA. Induction of remission was dose and treatment-time-dependent. The present paper reviews theoretical application of rHuIL-1Ra in patients with RA and summarizes results of published clinical trials of the drug.

• Authors: Aleksandra Zoń-Giebel, Anna Kotulska, Sebastian Giebel, Sham A Cader, Eugeniusz Józef Kucharz
• Journal: Przeglad lekarski (Przegl Lek) Vol. 59 Issue 11 Pg. 916-8 ( 2002) ISSN: 0033-2240 [Print] Poland
• Vernacular Title: Antagonista receptora interleukiny-1 w leczeniu reumatoidalnego zapalenia stawów.
• PMID: 12715722 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Antirheumatic Agents
• IL1RN protein, human
• Interleukin 1 Receptor Antagonist Protein
• Receptors, Interleukin-1
• Sialoglycoproteins
• Methotrexate

Topics

• Antirheumatic Agents (pharmacology, therapeutic use)
• Arthritis, Rheumatoid (drug therapy)
• Drug Therapy, Combination
• Humans
• Interleukin 1 Receptor Antagonist Protein
• Methotrexate (pharmacology, therapeutic use)
• Randomized Controlled Trials as Topic
• Receptors, Interleukin-1 (antagonists & inhibitors)
• Sialoglycoproteins (pharmacology, therapeutic use)